Resurgent Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Resurgent Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$563K	Buy	1,260 +111	+10%	+$51.8K	0.2%	121
2025 Q4	$521K	Buy	+1,149	New	+$495K	0.26%	111
2025 Q3	–	Sell	-607	Closed	-$270K	–	223
2025 Q2	$270K	Buy	607 +6	+1%	+$2.77K	0.15%	153
2025 Q1	$291K	Buy	601 +15	+3%	+$6.99K	0.18%	141
2024 Q4	$236K	Sell	586 -294	-33%	-$136K	0.14%	157
2024 Q3	$409K	Sell	880 -19	-2%	-$9.13K	0.24%	124
2024 Q2	$421K	Sell	899 -100	-10%	-$43.4K	0.26%	116
2024 Q1	$418K	Buy	999 +189	+23%	+$79.9K	0.22%	121
2023 Q4	$330K	Buy	810 +574	+243%	+$212K	0.2%	124
2023 Q3	$82.1K	Buy	236 +17	+8%	+$5.95K	0.06%	254
2023 Q2	$77.1K	Sell	219 -7	-3%	-$2.36K	0.05%	270
2023 Q1	$71.2K	Sell	226 -473	-68%	-$142K	0.05%	280
2022 Q4	$202K	Sell	699 -634	-48%	-$193K	0.11%	201
2022 Q3	$386K	Buy	1,333 +72	+6%	+$20.7K	0.26%	108
2022 Q2	$355K	Sell	1,261 -76	-6%	-$20.3K	0.23%	118
2022 Q1	$349K	Buy	+1,337	New	+$317K	0.22%	116

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Resurgent Financial Advisors's VRTX Position: Q1 2026 in Review

Resurgent Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 9.7% in Q1 2026, buying an estimated $51.8K and bringing the position to 1,260 shares worth $563K. The position accounts for 0.2% of the portfolio, ranked #121.

Resurgent Financial Advisors first reported a position in VRTX in Q1 2022 and has held it in 16 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Resurgent Financial Advisors held 1,260 shares of Vertex Pharmaceuticals worth $563K as of Q1 2026.
Resurgent Financial Advisors bought 111 Vertex Pharmaceuticals shares in Q1 2026, an estimated $51.8K.
Vertex Pharmaceuticals made up 0.2% of Resurgent Financial Advisors's portfolio in Q1 2026, its #121 holding.
Resurgent Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Resurgent Financial Advisors's 13F filing for Q1 2026, filed 13 May 2026.